Reported 2 days ago
The FDA has announced the resolution of the two-and-a-half-year shortage of Novo Nordisk's diabetes drug Ozempic and obesity treatment Wegovy, coinciding with the end of shortages for Eli Lilly's competing drugs. Pfizer's CEO Albert Bourla has been appointed as the new chair of PhRMA, emphasizing the need to collaborate on addressing chronic diseases and ensuring access to affordable medications.
Source: YAHOO